| Size | Price | Stock | Qty |
|---|---|---|---|
| 100g |
|
||
| Other Sizes |
| Targets |
Tetramethylammonium acetate hydrate does not have a defined biological target as a therapeutic agent. It is a quaternary ammonium salt used as a research reagent and phase-transfer catalyst. The tetramethylammonium cation is known to block potassium channels, but this compound is not used for this purpose pharmacologically. Its utility lies in its chemical properties rather than biological activity.
|
|---|---|
| ln Vitro |
Specific in vitro activity data for Tetramethylammonium acetate hydrate as a pharmacological agent are not documented in the literature. It is used as a research reagent rather than as a drug substance. The tetramethylammonium cation has been studied for its effects on potassium channels, but this compound is primarily used for its chemical properties. It is not characterized for direct biological activities.
|
| ln Vivo |
Tetramethylammonium acetate hydrate is not used for in vivo pharmacological activity assessment as a drug compound. Its primary applications are as a research reagent and phase-transfer catalyst. The compound is not intended to be administered to animals for pharmacological studies. Its chemical properties make it useful in organic synthesis and analytical chemistry.
|
| Enzyme Assay |
As a research reagent, Tetramethylammonium acetate hydrate is not typically used in enzyme/receptor binding assays. Its role is as a phase-transfer catalyst and electrolyte. When used in research, it may be employed in electrochemical studies or as a reagent in organic synthesis. Standard chemical protocols are employed for its use, rather than biochemical assay procedures.
|
| Cell Assay |
Tetramethylammonium acetate hydrate is not used in cell-based assays as a test compound. Its primary applications are as a research reagent and phase-transfer catalyst. The compound is not characterized for direct cellular effects. It may be used in studies of ion channel function, as tetraethylammonium is a known potassium channel blocker, but this compound is primarily used for its chemical properties.
|
| Animal Protocol |
Tetramethylammonium acetate hydrate is not used in animal studies as a pharmacological agent. Its primary applications are as a research reagent and phase-transfer catalyst. The compound is not intended to be administered to animals for efficacy evaluations. Its chemical properties make it useful in organic synthesis and analytical chemistry.
|
| ADME/Pharmacokinetics |
Tetramethylammonium acetate hydrate has a molecular formula of C₆H₁₇NO₃ and a molecular weight of 151.20 g/mol. It appears as a white crystalline solid and is used as a biochemical reagent for life science research. The compound is hygroscopic and should be stored under appropriate conditions. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Tetramethylammonium acetate hydrate is intended for research use only and is not approved for human therapeutic applications. As a research chemical, comprehensive toxicological data are not available in the publicly accessible literature. Standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. The compound should be handled in well-ventilated areas with proper waste disposal procedures.
|
| References |
[1]. Nanae Kikui, et al. Synthesis of Enol Esters through Silver-catalyzed or -mediated Hydroacyloxylation of Internal Alkynes. Chemistry Letters. 2018, Vol.47, No.2. 141-143
|
| Additional Infomation |
Tetramethylammonium acetate hydrate (TMAAc hydrate) (CAS#: 1266615-86-4) has a molecular formula of C₆H₁₇NO₃ and a molecular weight of 151.20 g/mol. It is a quaternary ammonium salt used as a biochemical reagent for life science research. This compound is not a drug and has not undergone clinical trials.
|
| Molecular Formula |
C6H17NO3
|
|---|---|
| Molecular Weight |
151.20
|
| Exact Mass |
151.12
|
| CAS # |
1266615-86-4
|
| Related CAS # |
Tetramethylammonium iodide;75-58-1;Tetramethylammonium hydrogensulfate;80526-82-5;Tetramethylammonium 4-methylbenzenesulfonate;3983-91-3;Tetramethylammonium tetrafluoroborate;661-36-9;Tetramethylammonium hexafluorophosphate;558-32-7;Tetramethylammonium bromide;64-20-0;Tetramethylammonium acetate;10581-12-1;Tetramethylammonium sulfate;14190-16-0;Tetramethylammonium perchlorate;2537-36-2;Tetramethylammonium (dichloroiodate);1838-41-1
|
| PubChem CID |
70699468
|
| Appearance |
Colorless to off-white Solid-Liquid Mixture
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
10
|
| Complexity |
44.6
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[O-]C(C)=O.O.[N+](C)(C)(C)C
|
| InChi Key |
CWLWVEZPAROZNJ-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C4H12N.C2H4O2.H2O/c1-5(2,3)4;1-2(3)4;/h1-4H3;1H3,(H,3,4);1H2/q+1;;/p-1
|
| Chemical Name |
tetramethylazanium;acetate;hydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.6138 mL | 33.0688 mL | 66.1376 mL | |
| 5 mM | 1.3228 mL | 6.6138 mL | 13.2275 mL | |
| 10 mM | 0.6614 mL | 3.3069 mL | 6.6138 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
